A Phase I, Open-Label, Dose-Escalation Study of the Safety and Pharmacokinetics of RX108 in Patients with Advanced or Metastatic Solid Tumours.

Trial Profile

A Phase I, Open-Label, Dose-Escalation Study of the Safety and Pharmacokinetics of RX108 in Patients with Advanced or Metastatic Solid Tumours.

Recruiting
Phase of Trial: Phase I

Latest Information Update: 20 Jun 2016

At a glance

  • Drugs RX 108 (Primary)
  • Indications Solid tumours
  • Focus Adverse reactions; First in man; Pharmacodynamics; Pharmacokinetics
  • Sponsors Suzhou NeuPharma
  • Most Recent Events

    • 10 Jun 2015 New trial record
    • 08 Jun 2015 Dosing of this Phase I study has been commenced, as reported in Suzhou NeuPharma media release.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top